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Background:  During the last decade there was a huge progress in the available therapies for chronic 
rheumatic conditions. The discovery, testing and implementing of the new therapies was enabled by 
numerous clinical trials which exposed the rheumatology patients more than ever to the challenges 
of clinical research.  There is no evidence of previous reports which investigated the perception of 
rheumatology patients in relation to their willingness to participate in clinical trials. However, in 
certain disciplines with longer history of clinical research, such as oncology, the literature data offer 
suitable examples of questionnaire-based research addressing both the clinicians and patients’ 
perceptions. We felt that there was a need to investigate the patients’ self-reported views related to 
rheumatology clinical research in order to address unexplored areas that would hopefully facilitate 
in the future their involvement in research. There is a very well justified trend to involve patients in 
the design of clinical trials and research activities in general and also to empower them in controlling 
their medical condition by providing appropriate access to scientific information. The patient- 
centred educational programs available nowadays in many hospitals have proven the benefits of 
putting the patient in the driven seat of their disease control. This is possible by ensuring patients’ 
access to suitable education about the management of rheumatologic diseases and also by enabling 
their access to the interdisciplinary teams that manage their condition.    
Materials and methods:  We conducted a cross-sectional survey of patients attending outpatient 
rheumatology clinics. The aim or our questionnaire-based study was to explore the patients’ 
perception of knowledge related to clinical trials in rheumatology, targeting patients with minimal 
and no previous exposure to clinical trials. The questionnaire is not validated as it was used for the 
first time in rheumatology patients and it was adapted from version used in a recent study 
investigating the cancer patients’ knowledge and attitudes towards clinical research (Cameron et 
al.,2003) (1). The survey was completed by outpatients attending University College London Hospital 
general rheumatology clinics from July to August 2013. The questionnaire was offered to all the 
patients attending randomly selected clinics. The patients were considered eligible if they were 18 
years of age or older and able to understand, speak and read English. They were approached in 
person by their rheumatologist and asked if they wanted to complete a questionnaire described as 
addressing the knowledge, understanding and concepts about clinical research. The study was 
approved as a local audit and the results of this survey were employed for designing educational 
activities for potential research patients and public coordinated and organised by the UCLH Clinical 
Research Facility, where our research activity is currently taking place.  
As there are no available educational programs addressing the principles of clinical research in 
rheumatology in our hospital, we wanted to objectify areas where patients would have identified 
the need for more information. The questionnaire comprised two demographic questions, two 5-
point Likert opinion questions, 22 true/false/unsure knowledge questions, and one free space 
question addressing what would help the participant to the survey to understand better clinical 
trials.  We collected demographic information about sex, age, date of the first visit to the 
rheumatology department, previous exposure to clinical trials, and level of education. The 
participation was voluntary and implied written consent. We haven’t included any of the patients’ 
identifiable data on the data base generated by this study. The patients haven’t been provided with 
any help or explanation when completing the questions and data were collected even from 
incomplete questionnaires. 
The patient survey was shared with the senior members of the UCLH rheumatology department who 
provided feedback which optimised its simplicity and clarity. The questionnaire was also shared with 
rheumatologist colleagues from Addenbrooke’s Hospital, Cambridge for a similar purpose.  
Statistical Analysis: Descriptive statistics were used to assess the proportion of correct answers and 
to assess the patient knowledge and characteristics. We calculated a questionnaire score for each 
participant by giving 1 point to every correct answer and each “unsure” and incorrect answer, 0 
points. T-test, Pearson correlation coefficients and analysis of variance statistical techniques were 
used to investigate patient characteristics associated with questionnaire scores. Logistic regression 
was employed to explore if the questionnaire score was related to the willingness to participate in 
clinical research. Statistical significance was defined at α=0.05 level. 
Results:  85 patients returned the questionnaires and 5 declined to complete it for different reasons 
(response rate 94.4%). 33 questionnaires from the returned ones were incomplete (38.8%). The 
lowest response rate was recorded in relation to the question number 22, where patients have to 
complete a free-text space asking what would help them in understanding clinical trials better 
(response rate 70.6%), followed by the question regarding the date of their first visit to our 
rheumatology clinics (response rate 92.9%) and the one about their diagnosis (response rate 94.1%. 
The rest of the questions have a response rate of above 95.2%.  
The median age of our respondents was 51 years and 25.8% were men. 25 patients (29.4%) were 
seen as new patients, and 60 (70.5%) are under regular follow-up for the management of 
rheumatoid arthritis (45.8%), osteoporosis (24.7%), osteoarthritis (14.1%) and other conditions 
(median duration of follow-up was 3 +/- 0.74 years). Under a quarter (21.1%) of patients had 
previously participated in clinical research, and 45% of patients agreed and strongly agreed that they 
have a good understanding about clinical trials, 27% were neutral about this statement and 28% 
disagreed.  
The mean number of correct answers to the 19 research knowledge questions was 10.5+/-2.87 
(56.1+/-15.1%) with a median number of correct answers of 11 (Table 1).  
The biggest consensus was reached on the following points: a clinical trial is a test of an 
experimental drug (77.6% agreement); statistics help to decide whether an experimental treatment 
is better than the available treatments (76.5%); the consent explains the known risks and benefits 
from being in a specific clinical study (75.2%); proving the efficacy of a drug in vitro is not enough to 
enable its use in humans (74.2%). Specific questions about definitions of placebo, standard vs. 
experimental treatment and randomisation generated a significant degree of uncertainty (52.9%, 
52.9%, and 50.5% respectively of patients replied “I don’t know”). Only a small proportion of 
patients (n=23, 27%) recognised that a standard treatment could be given in association with 
placebo and were aware that once the consent form is signed there is no mandatory participation 
until the end of the trial (n=27, 31.8%). Only 41.2% of patients (n=35) recognised that a clinical trial 
might require more visits to the hospital than patients receiving usual treatments and 54.1% of 
patients (n=46) considered that doctors personally received money in the UK if they recruit patients 
in clinical trials. The main incentive for participation in research was the hope for better care and 
more time with the clinician (45.8%). 
 
 
TABLE 1    Patients’ characteristics 
 
Characteristic Value 
Patients (n) 85 
Mean age (years) 50.9+/-16.3 
Sex [n(%)] 
Men 
Women 
 
22 (25.8) 
63 (74.2) 
Diagnosis [n(%)] 
Rheumatoid arthritis 
Osteoporosis 
Osteoarthritis 
Others 
Not known 
 
39 (45.8) 
14(16.4) 
7 (8.2) 
16 (18.8) 
9 (10.6) 
Time since first visit in the 
rheumatology department (years) 
Median 
Range 
No response [n(%)] 
 
 
3 
0.0-35.0 
3 (3.5) 
Education [n(%)] 
No formal education 
 
8 (9.4) 
Grade school 
Secondary school 
Trade/college/university 
Post-university 
No response 
2 (2.4) 
16 (18.9) 
37 (43.5) 
19 (22.3) 
3 (3.5) 
Understand clinical trials? [n(%)] 
Strongly disagree 
Disagree 
Neutral 
Agree 
Strongly agree 
Missing 
 
4 (4.7) 
7 (8.2) 
27 (31.8) 
28 (32.9) 
17 (20) 
2 (2.4) 
Join a clinical trial/ [n(%)] 
Strongly disagree 
Disagree 
Neutral 
Agree 
Strongly agree 
Missing 
  
3 (3.5) 
8 (9.4) 
35 (41.2) 
20 (23.6) 
16 (18.8) 
3 (3.5) 
Correct answers (% of total) 
Mean 
Median 
Range 
 
56.1+/-15.1 
55.3 
0.0-100 
 
 
 
 
  
 
TABLE 2   
Relationship between patient demographics, percentage of correct responses to research 
knowledge questions, and likelihood of participating in a clinical trial. 
 
 
Characteristic 
 
Patients 
(n) 
 
Mean 
correct 
answer (%) 
 
p Value 
 
Agree or strongly 
agree to join a 
clinical trial 
[n(%)] 
 
p value 
Age 
<55 Years 
+55 years 
 
49 
36 
 
35.4+/-13.6 
30.4+/-15.9 
 
0.14 
 
23 (46.9) 
13 (36.1) 
 
0.13 
Sex  
Men 
Women 
 
22  
63  
 
38.9+/16 
31.8+/15 
 
0.14 
 
9 (40.9) 
27 (42.8) 
 
0.32 
Diagnosis  
Rheumatoid arthritis (RA) 
Osteoporosis 
Osteoarthritis (OA) 
Others 
Not known 
 
39  
14 
7  
16  
9 
 
40.5+/-21.3 
37.5+/-13.3 
32.3+/-16.5 
40.7+/-9.1 
28.1+/-26 
 
N.S. 
 
 
 
 
 
27 (69.2) 
9 (64.2) 
2 (28.5) 
6 (37.5) 
3 (33.3) 
 
N.S 
Time since first visit in the 
rheumatology department 
(years) 
<1 year 
>1 year 
 
 
36 
49 
 
 
36.2+/-18.7 
36.3+/-14.7 
 
 
0.49 
 
 
13 (36.1) 
23 (46.9) 
 
 
0.22 
  
Education 
Trade/college/university 
and post-graduate 
Other 
 
56 
29 
 
39.4+/-13.1 
29.8+/-20.4 
 
0.013 
 
49 (87.5) 
14 (48.2) 
 
0.001 
Understand clinical trials 
Agree and strongly agree 
Other 
 
55 
30 
 
38.1+/-15.8 
34.4+/-17.8 
 
 
0.15 
 
24 (43.6) 
22 (73.2) 
 
 
0.021 
Join a clinical trial 
Agree or strongly agree 
Other 
  
45 
40 
 
39.4+/-15.3 
37.7+/-27.2 
 
0.032 
 
N/A 
 
Previous trial 
Yes 
No 
 
17 
68 
 
36.4+/-16.8 
40.2+/-15.2 
 
0.18 
 
14 (82) 
32 (47.5) 
 
0.001 
 
N.S. –no significant statistical difference between any of the groups.  
 
Patients with higher level of education (trade/college/university or postgraduate) had significantly 
higher knowledge scores than those with lower level of education (mean correct answers 39.4+/-
13.1 vs. 29.8+/-20.4, p=0.013). They also expressed in a higher proportion the willingness to take 
part in clinical trials (87.5% vs. 48.2%, p<0.001). Patients who agreed or strongly agreed with the 
statement “I have a good understanding about how clinical trials work” were less likely to take part 
in clinical trials the ones who didn’t agree with this statement (43.6% vs. 73.2%, p=0.021). The 
patients who agreed to participate in clinical trials provided significantly more correct answers to the 
questions related to research knowledge (mean correct answers 39.4+/-15.3% vs. 37.7+/-27.2%, 
p=0.032). Previous participation in clinical research wasn’t associated with higher proportion of 
correct answers (mean correct answers 36.4+/-16.8% vs. 40.2+/-15.2%, p=0.18); however patients 
previously recruited in clinical trials more commonly agreed and strongly agreed to take part in again 
in the future (82% vs.47.5%, p=0.001). 
 
In response to the question “What would help you in understanding clinical trials better” 60 patients 
(70.6%) provided text comments. The most frequent requirement was for more information 
including leaflets, discussions with the research team and website information (n=52, 86.7%). A 
small proportion of patients stated that taking part in a clinical trial (n=3, 5%) and being provided 
with clinical data from previous trials (n=2, 3.33%) will help them understand the principles of 
clinical research. Information concerning the risks and benefits of the procedures and treatments in 
specific studies was requested only by one patient.  
Only 9.4% would consider the option of taking part in clinical research because of their poor disease 
control, but this correlated well with patients’ previous participation in research (r=0.71; p<0.05). 
The lack of understanding of research principles correlated with the lack of willingness to participate 
in clinical trials (r= 0.72; p<0.05). 
 
Conclusions: The results of our study revealed that patients lack information about clinical trials and 
have difficulty understanding the principles of medical research. In is widely recognised that 
improvement in patients’ understanding of the principles of clinical research could improve interest 
in and recruitment to clinical trials. Our questionnaire revealed that the correct response rate to the 
knowledge questions was only slightly better than pure change (56.1%), which is extremely similar to 
the findings of the cancer patients’ study that we adapted the questionnaire from (1). Significant 
correlation of higher proportion of correct answers with higher level of education and previous 
participation in clinical research was evident in our study but inconsistently found in other cancer 
studies (3, 4). The need for more clinician time was perceived as one of the incentives to enrol in 
clinical research, showing that research could improve our patients’ experience of care. Also, the 
hope for a better disease control was one of the most important incentives to take part in research.  
 
 
 
Discussions: 
 
There are only a few studies investigating rheumatology patients’ perception related to treatments 
(2), telephone helpline usefulness (5) or impact of the physical environment on treatment delivery 
and patients’ experience (6). Ethical issues related to rheumatology clinical trials design was another 
area on interest for rheumatologists (7); however no previous study explored the experience of 
rheumatology patients involved in clinical research or their knowledge about clinical trials.  
 
The lack of systematic analysis of advantages and disadvantages for participating in clinical research 
was highlighted many years ago, in a study from 1985 exploring the attitudes of patients enrolled in 
two clinical trials (6). The patients reported that the time spent with the clinician and additional 
medical monitoring, as well as the access to a “second opinion” and reassurance received during the 
participation in a clinical trial were more important than the actual benefit of the trial intervention 
(8). In the same study, altruistic motivation to participate was reported by 65% of the patients 
recruited in both clinical trials.  
 
Previous studies investigated the recruitment experience in clinical trials, which is one of the main 
factors that shape patients’ perception about clinical research (9-11).  Our study was designed to 
address a group of patients with minimal experience of recruitment in clinical trials as we were 
interested in assessing their perception more than their experience related to clinical research 
activities.  
 
Different concepts, such as general health, medical history, health and illness perceptions, attitude 
to clinician and information, general attitudes and expectations towards the clinical trials were 
included in a Health Belief Model (HBM) and were identified as determinants of patients 
participation in clinical studies requiring informed consent (12). If the willingness to participate in 
clinical research is defined as an illness coping behaviour weighted by patients own beliefs for and 
against the trial, the conclusion might be that patients are quite predictable in their decision to take 
part in research, as observed by Verheggen at al., 1998 (12). However, there is a recognised variety 
of psychological factors involved in every individual decision related to participation in clinical 
research activities, such as: personal benefits from participation in a trial, altruistic and non-altruistic 
motives, what do patients perceive as disadvantages of clinical research and effects of the trial 
medication, and previous experience of clinical research (13, 14). 
 
Previous research identified the attractiveness to participate in clinical research as being linked to 
gaining personal benefit, such as access to latest research in their condition and new treatments, 
specialist team expertise, more frequent monitoring and active involvement in their health care (15). 
However, ethnical disparities in enrolment in clinical trials were noted in the past and efforts were 
allocated to engage diverse communities in research and incentivise the industry to help people 
overcome logistical barriers to participation in clinical trials (16).  
 
Several studies exploring oncologic patients highlighted the huge impact that the pressure caused by 
the difficult diagnosis and perception of clinical trials as the only remaining option experienced by 
this category of patients (17). On the other hand, oncology patients expressed positive expectations 
in relation to cancer treatments when enrolled in early phase clinical trials, suggesting that optimism 
and positive thoughts and expectations are more influential than patients understanding of the 
concepts of clinical research and treatment uncertainties (18).  
 
In contrast to the results of our study, Korean cancer patients’ willingness to participate in clinical 
trials wasn’t influenced by the patients’ level of education, despite the good correlation between 
higher level of education and economic status with patients’ awareness of clinical trials (19). 
However, patients with previous experience in clinical trials had a greater willingness to participate 
in clinical research, similar to our study, suggesting that the experience of taking part in clinical trials 
was a positive for both, rheumatology and cancer patients. 
  
Another similarity between these two categories of patients was found in the main reasons for 
participating in clinical research, which were the physician recommendation and expectation of 
effectiveness of a new drug. An Indian study published in 2013 revealed that physician advice and 
access to free medication along with family advice were the main reasons for taking part in a clinical 
trial, but otherwise the knowledge about clinical research lacked with 20% of patients unable to 
remember the study they took part in (20). A huge proportion of patients from Kenya relies on their 
clinician advice as well, and tend to not scrutinise trial details when agreeing to participate in clinical 
trials according to Naanyu et al., 2014 (21) . 
 
We didn’t explore the patients’ perception of the informed consent process as our cohort included 
only a minority of patients with previous experience of clinical research. A study from 2008, focused 
on the informed consent process perception indirectly suggested that patients’ confidence in their 
physicians and drug effectiveness was also good, as they reported not wanting to withdraw from a 
clinical trials because of the side-effects and the conviction that research won’t compromise their 
care (22). 
 
Positive experience of taking part in clinical trials was also reported by another questionnaire study, 
where patients stated that they were given more time to ask questions and discuss the treatment 
options in the research setting than in the usual clinical setting. People taking part in clinical trials 
also reported that appropriate information about the study was provided (23).    
 
In conclusion, our questionnaire study highlighted a 
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